The therapy in question, dubbed…
The therapy in question, dubbed C-CAR031, is based on AstraZeneca’s [...]
Immunology biotech Agomab…
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both [...]
Vedanta Biosciences has…
Vedanta Biosciences has “significantly reduced” its headcount to channel its [...]
ImmunityBio has reported ongoing…
ImmunityBio has reported ongoing complete responses of up to 15 [...]
The leaders of Chugai…
The leaders of Chugai Pharmaceutical are tired of their company [...]
iRegene’s NouvNeu001 earns dual…
iRegene’s NouvNeu001 earns dual FTD/RMAT status, a first for iPSC [...]
After last year’s upheaval at…
After last year’s upheaval at the CDC’s Advisory Committee on [...]
Ocugen has reported preliminary…
Ocugen has reported preliminary phase 2 data on its eye [...]
Italian pharma Alfasigma has…
Italian pharma Alfasigma has penned a 125 million euros ($145 [...]
Hopes were high Wednesday for a…
Hopes were high Wednesday for a billion-dollar megadeal—the kind the [...]